Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Hormone receptor conversion in metastatic breast cancer

K. Procházková, R. Vojtíšek, J. Vodička, J. Horová, P. Hošek, M. Skála, J. Šebek, J. Dostál, V. Přibáň, K. Pivovarčíková, O. Hes, V. Třeška, J. Moláček

. 2023 ; 28 (6) : 746-755. [pub] 20240216

Status not-indexed Language English Country Poland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24005765

BACKGROUND/OBJECTIVE: Hormone receptor (HR) status is one of the key factors in determining the treatment of breast cancer. Previous studies suggested that HR status may change in metastatic tissue. However, available studies focused mainly on primary biopsies and there are only few trials comparing HR status in the primary tumour and the metastasis using material from complete resection. The aim of the study was to determine the frequency of HR alterations in metastatic breast cancer. MATERIALS AND METHODS: The study retrospectively examines a total of 50 patients who underwent brain, lung, or liver metastasectomy for metastatic breast cancer between January 2000 and January 2019. RESULTS: HR conversion was observed in a total of 30 cases (60.0%), while HER-2/neu (human epidermal growth factor receptor 2) discrepancy surprisingly occurred only in one case (2.0%). A change in immunophenotype occurred in 28% of cases. Triple-negativity was more frequent in brain metastases (p = 0.039). CONCLUSIONS: We have confirmed that HR conversion between the primary tumour and its metastases occurs in a significant number of cases, which has important implications for further treatment decisions.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005765
003      
CZ-PrNML
005      
20240412131026.0
007      
ta
008      
240405s2023 pl f 000 0|eng||
009      
AR
024    7_
$a 10.5603/rpor.98730 $2 doi
035    __
$a (PubMed)38515821
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Procházková, Kristýna $u Department of Surgery, Charles University and University Hospital, Pilsen, Czech Republic
245    10
$a Hormone receptor conversion in metastatic breast cancer / $c K. Procházková, R. Vojtíšek, J. Vodička, J. Horová, P. Hošek, M. Skála, J. Šebek, J. Dostál, V. Přibáň, K. Pivovarčíková, O. Hes, V. Třeška, J. Moláček
520    9_
$a BACKGROUND/OBJECTIVE: Hormone receptor (HR) status is one of the key factors in determining the treatment of breast cancer. Previous studies suggested that HR status may change in metastatic tissue. However, available studies focused mainly on primary biopsies and there are only few trials comparing HR status in the primary tumour and the metastasis using material from complete resection. The aim of the study was to determine the frequency of HR alterations in metastatic breast cancer. MATERIALS AND METHODS: The study retrospectively examines a total of 50 patients who underwent brain, lung, or liver metastasectomy for metastatic breast cancer between January 2000 and January 2019. RESULTS: HR conversion was observed in a total of 30 cases (60.0%), while HER-2/neu (human epidermal growth factor receptor 2) discrepancy surprisingly occurred only in one case (2.0%). A change in immunophenotype occurred in 28% of cases. Triple-negativity was more frequent in brain metastases (p = 0.039). CONCLUSIONS: We have confirmed that HR conversion between the primary tumour and its metastases occurs in a significant number of cases, which has important implications for further treatment decisions.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vojtíšek, Radovan $u Department of Oncology and Radiotherapy, Charles University and University Hospital, Pilsen, Czech Republic $1 https://orcid.org/0000000173187927
700    1_
$a Vodička, Josef $u Department of Surgery, Charles University and University Hospital, Pilsen, Czech Republic
700    1_
$a Horová, Jana $u Department of Neurology, Charles University and University Hospital, Pilsen, Czech Republic
700    1_
$a Hošek, Petr $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Skála, Martin $u Department of Surgery, Charles University and University Hospital, Pilsen, Czech Republic
700    1_
$a Šebek, Jakub $u Department of Surgery, Charles University and University Hospital, Pilsen, Czech Republic
700    1_
$a Dostál, Jiří $u Department of Neurosurgery, Charles University and University Hospital, Pilsen, Czech Republic
700    1_
$a Přibáň, Vladimír $u Department of Neurosurgery, Charles University and University Hospital, Pilsen, Czech Republic
700    1_
$a Pivovarčíková, Kristýna $u Department of Pathology, Charles University and University Hospital, Pilsen, Czech Republic
700    1_
$a Hes, Ondřej $u Department of Pathology, Charles University and University Hospital, Pilsen, Czech Republic
700    1_
$a Třeška, Vladislav $u Department of Surgery, Charles University and University Hospital, Pilsen, Czech Republic
700    1_
$a Moláček, Jiří $u Department of Surgery, Charles University and University Hospital, Pilsen, Czech Republic
773    0_
$w MED00154188 $t Reports of Practical Oncology and Radiotherapy $x 1507-1367 $g Roč. 28, č. 6 (2023), s. 746-755
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38515821 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412131019 $b ABA008
999    __
$a ok $b bmc $g 2076019 $s 1215527
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 28 $c 6 $d 746-755 $e 20240216 $i 1507-1367 $m Reports of Practical Oncology and Radiotherapy $n Rep Pract Oncol Radiother $x MED00154188
LZP    __
$a Pubmed-20240405

Find record

Citation metrics

Archiving options